Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Dermatology

What Medications Are Linked to Bullous Pemphigoid?

At a Glance

Some medicines—especially DPP-4 inhibitors for diabetes, certain diuretics, and immune checkpoint inhibitors—are linked to bullous pemphigoid, but the overall risk is low. Do not stop a prescription yourself; seek medical evaluation and discuss safer alternatives.

Yes, certain diabetes and cardiovascular medications are associated with an increased risk of developing bullous pemphigoid [1]. This is often referred to as drug-associated or drug-induced bullous pemphigoid. In these cases, a medication is suspected of triggering the immune system to mistakenly attack the tissue just beneath the top layer of skin, leading to blistering.

While the overall absolute risk of developing bullous pemphigoid from these drugs is very low, observational studies have found strong associations with specific classes of medications, particularly DPP-4 inhibitors (used for diabetes) and certain diuretics (used for fluid retention and blood pressure) [2][1]. However, because many patients take these medications without ever developing the disease, an association does not definitively prove that the drug caused the blistering in any individual person.

Urgent Warning Signs

If you develop new blistering after starting a medication, do not assume it is bullous pemphigoid. Severe drug reactions can be medical emergencies. Seek immediate medical attention if you experience rapidly spreading or painful blisters, skin peeling, fever, facial swelling, sores in your mouth or eyes, difficulty breathing, or signs of infection (like pus or worsening redness).

Diabetes Medications (DPP-4 Inhibitors)

The strongest reported medication association for bullous pemphigoid involves a class of type 2 diabetes medications called DPP-4 inhibitors, also known as “gliptins” [2][3]. Observational studies suggest that not all gliptins carry the same level of risk. Some data points to a stronger association with vildagliptin and linagliptin, while the evidence for others like sitagliptin is less consistent [4][5].

Importantly, blistering may not start immediately. The time between starting a gliptin and developing symptoms can range from just a few weeks to several years [6][7]. Because of this long delay, it is easy to miss the connection between a medication you have taken safely for years and a sudden outbreak of blisters.

Diuretics and Other Cardiovascular Medicines

Certain medications used to manage fluid overload, heart failure, and high blood pressure are also associated with bullous pemphigoid. Loop diuretics, such as furosemide, have been identified as potential triggers [1][8]. Other diuretics, including thiazides and potassium-sparing diuretics like spironolactone, have also been reported in case studies, though the strength of the evidence is not as well-quantified as it is for DPP-4 inhibitors [9][10].

Other Potential Medication Associations

Researchers have identified other medications that may trigger bullous pemphigoid, though the strength of the evidence varies:

  • Immune checkpoint inhibitors (PD-1/PD-L1 inhibitors): A type of cancer immunotherapy that has a strong established link. These can cause blistering even months after the treatment has stopped [1][11].
  • Antibiotics and other drugs: Penicillin derivatives, ACE inhibitors (for blood pressure), and levetiracetam (for seizures) have been reported as potential triggers in some studies, but further research is needed to confirm these links [1][12].

How Doctors Confirm the Diagnosis

Your doctor cannot diagnose drug-associated bullous pemphigoid just by looking at your medication list. Diagnosis typically involves a physical examination and a skin biopsy, where a small sample of a blister and the surrounding skin is tested using direct immunofluorescence to look for specific immune deposits [1].

Differences in Symptoms

Drug-associated bullous pemphigoid often looks clinically identical to idiopathic bullous pemphigoid (disease that occurs without a known cause or medication link) [1]. However, there can be subtle differences. For example, some studies suggest that cases associated with gliptins may present with less severe inflammation, less redness (erythema), and fewer hives (urticaria) [13].

Blood tests checking for specific bullous pemphigoid antibodies (like BP180 and BP230) are also used as an adjunct to diagnosis. In drug-associated cases, these antibody levels can sometimes be lower or even negative [14]. Because these are only tendencies, a negative blood test does not rule out the disease, and these tests do not replace a proper biopsy.

What Happens If a Medication is Suspected?

Never stop taking prescribed diabetes, heart, or blood pressure medications without speaking to your doctor. Doing so can lead to dangerous spikes in blood sugar or fluid buildup.

If your clinical team suspects a medication is contributing to your blisters, they will carefully weigh the risks of the medication against its benefits for your overall health [1]. If they decide it is safe to stop the drug, they will help you transition to an alternative treatment.

Stopping the suspected medication is rarely a quick fix. While a small number of patients see their blisters resolve after stopping the drug [15], many others require standard bullous pemphigoid treatments—such as topical or oral corticosteroids—to calm the immune system [16][17]. Improvement is highly variable; it may take weeks or months, and some patients continue to have disease activity despite stopping the drug [6][18]. Therefore, active treatment for your blisters should not be delayed while waiting to see if a medication change helps.

Common questions in this guide

Which diabetes drugs are most associated with bullous pemphigoid?
DPP-4 inhibitors, also called gliptins, have the strongest reported association with bullous pemphigoid. Studies suggest the association may be stronger with vildagliptin and linagliptin, while findings for sitagliptin are less consistent. The overall risk remains low, and an association does not prove that a drug caused blistering in a particular person.
Can diuretics or blood pressure medicines trigger bullous pemphigoid?
Yes. Loop diuretics such as furosemide have been associated with bullous pemphigoid, and thiazide diuretics, spironolactone, and ACE inhibitors have also been reported. The strength of evidence differs among medicines, so a clinician must review the full medication history.
How soon can medication-related bullous pemphigoid appear?
Blistering may begin within weeks of starting a medicine or after the medicine has been taken for several years. Immune checkpoint inhibitors can be linked to blistering even months after treatment stops. A long delay can make the medication connection difficult to recognize.
Should I stop my medicine if I develop blisters?
Do not stop a prescribed diabetes, heart, or blood pressure medicine on your own. Contact your clinician so they can weigh the medicine’s benefits and risks, arrange a safe alternative if needed, and begin treatment for the blisters without unnecessary delay.
How do doctors determine whether a medication caused bullous pemphigoid?
Doctors use the timing of symptoms, a complete medication history, and a skin examination, but a medication list alone cannot confirm the cause. A skin biopsy examined with a special laboratory test called direct immunofluorescence is typically used, and blood tests for BP180 or BP230 antibodies may provide additional information. Negative blood tests do not rule out bullous pemphigoid.
When are blisters after a new medicine an emergency?
Get immediate medical attention for rapidly spreading or painful blisters, skin peeling, fever, facial swelling, sores in the mouth or eyes, trouble breathing, or signs of infection such as pus or worsening redness. These symptoms can signal a severe drug reaction or another urgent problem and should not be assumed to be bullous pemphigoid.
Will bullous pemphigoid go away after the suspected medicine is stopped?
Some people improve after the suspected medicine is stopped, but stopping it is not always a quick or complete solution. Blisters may continue for weeks or months, and many people need topical or oral corticosteroids to control the immune reaction. Follow-up is important even after a medication change.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which of my current medications, including over-the-counter drugs and supplements, have a reported association with bullous pemphigoid?
  2. 2.If a medication like a DPP-4 inhibitor or diuretic is suspected, how do we weigh the risks of stopping it against the benefits of keeping my underlying condition controlled?
  3. 3.If we decide to stop a suspected medication, what is the safest way to transition to an alternative treatment, and what symptoms should I watch for?
  4. 4.How will we assess whether a medication contributed to my bullous pemphigoid, and should this suspected reaction be added to my medical record?
  5. 5.What active treatments do I need for the blisters now, rather than waiting to see if a medication change helps?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    A Systematic Review of Drug-Induced Pemphigoid.

    Verheyden MJ, Bilgic A, Murrell DF

    Acta dermato-venereologica 2020; (100(15)):adv00224 doi:10.2340/00015555-3457.

    PMID: 32176310
  2. 2

    Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.

    Lee H, Chung HJ, Pawar A, et al.

    JAMA dermatology 2020; (156(10)):1107-1114 doi:10.1001/jamadermatol.2020.2158.

    PMID: 32697283
  3. 3

    DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.

    Jedlowski PM, Jedlowski MF, Fazel MT

    American journal of clinical dermatology 2021; (22(6)):891-900 doi:10.1007/s40257-021-00625-4.

    PMID: 34287770
  4. 4

    Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.

    Phan K, Charlton O, Smith SD

    The Australasian journal of dermatology 2020; (61(1)):e15-e21 doi:10.1111/ajd.13100.

    PMID: 31215644
  5. 5

    Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.

    Harano Y, Mitamura Y, Jiang P, et al.

    Journal of diabetes investigation 2023; (14(6)):756-766 doi:10.1111/jdi.14004.

    PMID: 36897510
  6. 6

    Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.

    Jha A, Misra A, Gupta R, et al.

    Diabetes & metabolic syndrome 2020; (14(3)):213-216 doi:10.1016/j.dsx.2020.03.001.

    PMID: 32172176
  7. 7

    Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.

    Sun L, Wang C, Wu C, et al.

    The Annals of pharmacotherapy 2022; (56(2)):205-212 doi:10.1177/10600280211022722.

    PMID: 34105395
  8. 8

    Identifying potential drug triggers for bullous pemphigoid: a disproportionality analysis of the FDA adverse event reporting system and systematic review of case reports.

    Mahesh R, Das K A, Thomas C, et al.

    Cutaneous and ocular toxicology 2025; (44(4)):431-463 doi:10.1080/15569527.2025.2554799.

    PMID: 40927818
  9. 9

    Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development.

    de Nicolas-Ruanes B, Fernandez-Lozano C, Gutierrez-Canales P, et al.

    International journal of dermatology 2025; (64(9)):1636-1643 doi:10.1111/ijd.17849.

    PMID: 40375473
  10. 10

    Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment.

    Bernard P, Antonicelli F

    American journal of clinical dermatology 2017; (18(4)):513-528 doi:10.1007/s40257-017-0264-2.

    PMID: 28247089
  11. 11

    Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases.

    Molina-Guarneros JA, Sainz-Gil M, Sanz-Fadrique R, et al.

    International journal of clinical pharmacy 2020; (42(2)):713-720 doi:10.1007/s11096-020-01003-6.

    PMID: 32140915
  12. 12

    Ciprofloxacin as a Trigger for Bullous Pemphigoid: The Second Case in the Literature.

    Cozzani E, Chinazzo C, Burlando M, et al.

    American journal of therapeutics 2016; (23(5)):e1202-4 doi:10.1097/MJT.0000000000000283.

    PMID: 26164023
  13. 13

    Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study.

    Salemme A, Fania L, Scarabello A, et al.

    Journal of the American Academy of Dermatology 2022; (87(1)):56-63 doi:10.1016/j.jaad.2022.02.036.

    PMID: 35240229
  14. 14

    Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.

    García-Díez I, Ivars-Lleó M, López-Aventín D, et al.

    International journal of dermatology 2018; (57(7)):810-816 doi:10.1111/ijd.14005.

    PMID: 29682739
  15. 15

    Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.

    Sugiyama S, Yamamoto T, Aoyama Y

    The Journal of dermatology 2022; (49(7)):697-702 doi:10.1111/1346-8138.16394.

    PMID: 35478414
  16. 16

    Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.

    Benzaquen M, Borradori L, Berbis P, et al.

    Journal of the American Academy of Dermatology 2018; (78(6)):1090-1096 doi:10.1016/j.jaad.2017.12.038.

    PMID: 29274348
  17. 17

    Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.

    Plaquevent M, Tétart F, Fardet L, et al.

    The Journal of investigative dermatology 2019; (139(4)):835-841 doi:10.1016/j.jid.2018.10.045.

    PMID: 30543900
  18. 18

    Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication.

    Shinohara Y, Iijima T, Sakurai S, et al.

    Clinical case reports 2020; (8(10)):2007-2012 doi:10.1002/ccr3.3047.

    PMID: 33088540

This page is for informational purposes only and does not constitute medical advice. Do not stop a prescribed medication without speaking with your doctor, especially if you develop blisters or other urgent symptoms.

Get notified when new evidence is published on Bullous pemphigoid.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.